FDA grants priority review for Novartis Kymriah for treating r/r DLBCL
US Food and Drug Administration (FDA) has assured priority review of Novartis supplemental Biological License Application (sBLA) for Kymriah suspension for intravenous infusion,…
Read More...
Read More...
